# US 2025/0149121 A1 · Detection of peptide structures for diagnosing and treating sepsis and covid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0149121 A1
- Document ID: US20250149121A1
- Status: Published application
- Kind: A1
- Application number: 18/681,704
- Filed: 2022-08-05
- Published: 2025-05-08
- Earliest claimed: 2021-08-07
- Assignees: Venn Biosciences Corporation
- Applicants: Venn Biosciences Corporation
- Inventors: Chad Eagle PICKERING; Gege XU; Hector Han-Li HUANG; Xin CONG
- Web page: https://patentgrep.com/patent/US20250149121A1

## CPC

- G16B 40/20: Supervised data analysis
- G16B 15/00: ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
- G16B 15/20: Protein or domain folding
- G16B 40/30: Unsupervised data analysis
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Embodiments disclosed herein generally relate to technologies for evaluating a biological sample obtained from a subject with respect to a sepsis state or coronavirus disease (COVID). Some methods relating to the technologies can include receiving peptide structure data corresponding to the biological sample obtained from the subject, identifying a peptide structure profile for the biological sample using the peptide structure data, and computing a disease indicator using the peptide structure profile and a model. The disease indicator can indicate whether the biological sample is positive for the sepsis state. The disease indicator can indicate whether the biological sample is positive for COVID. The peptide structure profile can comprise quantification data for a set of peptide structures associated with the sepsis state. The peptide structure profile can include peptides that are glycosylated, aglycosylated, or both. An additional step in the method can comprise generating at least one of a diagnosis output or a treatment output based on the disease indicator.

## Claims

### Claim 1

A method of determining whether a biological sample corresponds to a sepsis state, the method comprising:
inputting quantification data identified from peptide structure data for a set of peptide structures into a supervised machine learning model, wherein the set of peptide structures includes at least one peptide structure identified in Table 1;
analyzing the quantification data using the supervised machine learning model to generate a disease indicator that classifies the biological sample as corresponding to a cluster of a plurality of clusters that has a least distance to the biological sample, the plurality of clusters corresponding a plurality of states that includes the sepsis state; and
generating a diagnosis output based on the disease indicator.

### Claim 2 (depends on 1)

The method of claim 1, further comprising receiving peptide structure data corresponding to the biological sample obtained from a subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the at least one peptide structure comprises a glycopeptide structure defined by a peptide sequence and a glycan structure linked to the peptide sequence at a linking site of the peptide sequence, as identified in Table 1, with the peptide sequence being one of SEQ ID NOS: 24-49 as defined in Table 3.

### Claim 4 (depends on 1)

The method of claim 1, wherein the at least one peptide structure comprises an aglycosylated peptide structure defined by a peptide sequence, as identified in Table 1, with the peptide sequence being one of SEQ ID NOS: 50-54 as defined in Table 3.

### Claim 5 (depends on 1)

The method of claim 1, wherein the supervised machine learning model comprises at least one of a Support Vector Machine (SVM) classifier, a Support Vector Classifier (SVC) model, a linear classifier, a decision tree, a random forest algorithm, a k-Nearest Neighbors algorithm, a Naive Bayes algorithm, or a gradient boosting algorithm.

### Claim 6 (depends on 1)

The method of claim 1, further comprising:
training the supervised machine learning model using training data generated from an unsupervised machine learning model,
wherein the training data comprises a plurality of peptide structure profiles for a plurality of subjects and identifies a corresponding state of the plurality of states for each peptide structure profile of the plurality of peptide structure profiles; and
wherein the unsupervised machine learning model is trained to cluster the plurality of peptide structure profiles into the plurality of clusters.

### Claim 7 (depends on 1)

The method of claim 1, wherein the unsupervised machine learning model is a k-means clustering model.

### Claim 8 (depends on 1)

The method of claim 1, wherein a peptide structure profile of the plurality of peptide structure profiles for a corresponding subject of the plurality of subjects is selected based on a differential expression analysis of quantification metrics for a panel of peptide structures for the plurality of subjects.

### Claim 9 (depends on 8)

The method of claim 8, further comprising:
comparing, using the differential expression analysis, the quantification metrics corresponding to the panel of peptide structures for a first portion of the plurality of subjects diagnosed with the sepsis state to that of each portion of a set of other portions of the plurality of subjects to generate a set of comparisons; and
selecting a portion of the panel of peptide structures having a false discovery rate below 0.05 across the set of comparisons as the set of peptide structures.

### Claim 10 (depends on 9)

The method of claim 9, wherein the comparing comprises:
comparing the quantification metrics corresponding to the panel of peptide structures for the first portion of the plurality of subjects diagnosed with the sepsis state to that of a second portion of the plurality of subjects diagnosed with a symptomatic disease state of a coronavirus disease to generate a first comparison of the set of comparisons.

### Claim 11 (depends on 10)

The method of claim 10, wherein the comparing further comprises:
comparing the quantification metrics corresponding to the panel of peptide structures for the first portion of the plurality of subjects diagnosed with the sepsis state to that of at least one of:
a third portion of the plurality of subjects diagnosed with a common cold state to generate a second comparison of the set of comparisons;
a fourth portion of the plurality of subjects diagnosed with a healthy state to generate a third comparison of the set of comparisons;
a fifth portion of the plurality of subjects diagnosed with an asymptomatic state of the coronavirus disease to generate a fourth comparison of the set of comparisons.

### Claim 12 (depends on 1)

The method of claim 1, wherein the quantification data for a peptide structure of the set of peptide structures comprises at least one of a relative quantity, an adjusted quantity, a normalized quantity, a relative concentration, an adjusted concentration, or a normalized concentration.

### Claim 13 (depends on 1)

The method of claim 1, wherein the peptide structure data is generated using multiple reaction monitoring mass spectrometry (MRM-MS).

### Claim 14 (depends on 1)

The method of claim 1, wherein the sepsis state is selected from a group consisting of a mild sepsis state, a moderate sepsis state, or a severe sepsis state.

### Claim 15 (depends on 1)

The method of claim 1, further comprising:
creating a sample from the biological sample; and
preparing the sample using reduction, alkylation, and enzymatic digestion to form a prepared sample that includes a set of peptide structures.

### Claim 16 (depends on 1)

The method of claim 1, further comprising:
generating the peptide structure data from the prepared sample using multiple reaction monitoring mass spectrometry (MRM-MS).

### Claim 17 (depends on 1)

The method of claim 1, wherein generating the diagnosis output comprises:
generating a report that includes a diagnosis that the subject is positive for the sepsis state in response to the disease indicator classifying the biological sample as corresponding to the sepsis state.

### Claim 18 (depends on 1)

The method of claim 1, wherein the biological sample comprises at least one of a whole blood sample, a plasma sample, or a serum sample.

### Claim 19 (depends on 1)

The method of claim 1, further comprising:
generating a treatment output based on at least one of the diagnosis output or the disease indicator.

### Claim 20 (depends on 19)

The method of claim 19, wherein the treatment output comprises at least one of an identification of a treatment to treat the subject, a design for the treatment, a manufacturing plan for the treatment, or a treatment plan for administering the treatment.

### Claim 21 (depends on 19)

The method of claim 19, wherein the treatment comprises at least one antibiotic.

### Claim 22 (depends on 19)

The method of claim 19, wherein the treatment comprises at least one of a broad-spectrum antibiotic, a targeted antibiotic, or a vasopressor.

### Claim 23 (depends on 19)

The method of claim 19, wherein generating the treatment output comprises:
determining a dosage for a therapeutic to treat the subject based on at least one of the diagnosis output or the disease indicator.

### Claim 24 (depends on 19)

The method of claim 19, wherein the diagnosis output identifies that the biological sample is positive for the sepsis state and further comprising:
administering a therapeutic dosage of a therapeutic for the sepsis state to the subject, the therapeutic comprising one or more antibiotics.

### Claim 25

A method of identifying a sepsis-specific set of peptide structures for use in diagnosing a sepsis state, the method comprising:
receiving quantification data for a panel of peptide structures for a plurality of subjects diagnosed with a plurality of states, the plurality of states including the sepsis state;
comparing quantification metrics corresponding to the panel of peptide structures for a first portion of the plurality of subjects diagnosed with the sepsis state to that of each portion of a set of other portions of the plurality of subjects to generate a set of comparisons using a differential expression analysis;
selecting a portion of the panel of peptide structures having a false discovery rate below 0.05 across the set of comparisons as a set of peptide structures to be associated with the sepsis state,
wherein the set of peptide structures includes at least one glycopeptide structure defined by a peptide sequence and a glycan structure linked to the peptide sequence at a linking site of the peptide sequence;
analyzing the quantification data for the set of peptide structures for the plurality of subjects using an unsupervised machine learning model to cluster the plurality of subjects; and
training a supervised machine learning model to determine whether a biological sample obtained from a subject corresponds to the sepsis state or another state of the plurality of states.

### Claim 26 (depends on 25)

The method of claim 25, further comprising:
analyzing the biological sample obtained from the subject using the supervised machine learning model that has been trained to generate a disease indicator that indicates whether the biological subject is positive for the sepsis state.

### Claim 27 (depends on 25)

The method of claim 25, wherein the plurality of states further includes at least one of a common cold state, a healthy state, a symptomatic disease state of a coronavirus disease (COVID), or an asymptomatic disease state of the coronavirus disease.

### Claim 28 (depends on 25)

The method of claim 25, wherein the sepsis state is either a mild sepsis state or a severe sepsis state.

### Claim 29 (depends on 25)

The method of claim 25, wherein the unsupervised machine learning model comprises a k-means clustering model and wherein the supervised machine learning model comprises at least one of a Support Vector Machine (SVM) classifier, a Support Vector Classifier (SVC) model, a linear classifier, a decision tree, a random forest algorithm, a k-Nearest Neighbors algorithm, a Naive Bayes algorithm, or a gradient boosting algorithm.

### Claim 30 (depends on 25)

The method of claim 25, wherein the set of peptide structures includes at least three peptide structures identified in Table 1.

### Claim 31

A method of evaluating a biological sample obtained from a subject with respect to a sepsis state, the method comprising:
identifying a peptide structure profile for the biological sample using peptide structure data, the peptide structure profile comprising quantification data for a set of peptide structures associated with the sepsis state,
wherein the set of peptide structures includes at least two peptide structures from a selected group of peptide structures identified in Table 1; and
wherein at least two peptide structures in the selected group of peptide structures includes a glycopeptide structure defined by a peptide sequence and a glycan structure linked to a linking site of the peptide sequence;
computing a disease indicator using the peptide structure profile and a model, wherein the disease indicator indicates whether the biological sample is positive for the sepsis state; and
generating at least one of a diagnosis output or a treatment output based on the disease indicator.

### Claim 32 (depends on 31)

The method of claim 31, further comprising receiving peptide structure data corresponding to the biological sample obtained from the subject.

### Claim 33 (depends on 31)

The method of claim 31, wherein the model includes a supervised machine learning model that comprises at least one of a Support Vector Machine (SVM) classifier, a Support Vector Classifier (SVC) model, a linear classifier, a decision tree, a random forest algorithm, a k-Nearest Neighbors algorithm, a Naive Bayes algorithm, or a gradient boosting algorithm.

### Claim 34 (depends on 31)

The method of claim 31, wherein the model comprises a supervised machine learning model trained using an output of an unsupervised machine learning model that is trained to cluster a plurality of peptide structure profiles for a plurality of subjects according to a plurality of states, the plurality of states including the sepsis state.

### Claim 35 (depends on 31)

The method of claim 31, wherein the treatment output comprises at least one of an identification of a treatment to treat the subject, a design for the treatment, a manufacturing plan for the treatment, or a treatment plan for administering the treatment.

### Claim 36 (depends on 31)

The method of claim 31, further comprising:
administering a therapeutic dosage of a therapeutic for the sepsis state to the subject based on the at least one of the diagnosis output or the treatment output, the therapeutic comprising one or more antibiotics.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30)

A method of designing a treatment for a sepsis state in a subject, the method comprising:
designing a therapeutic for treating the subject in response to identifying the subject as being positive for the sepsis state using the method of any one of claims 1-23, 25-30, or 31-35.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30)

A method of planning a treatment for a sepsis state in a subject, the method comprising:
generating a treatment plan for treating the subject in response to identifying the subject as being positive for the sepsis state using the method of any one of claims 1-23, 25-30, or 31-35.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30)

A method of manufacturing a treatment for a sepsis state in a subject, the method comprising:
manufacturing a therapeutic for treating the subject in response to identifying the subject as being positive for the sepsis state using the method of any one of claims 1-23, 25-30, or 31-35.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30)

A method of treating a sepsis state in a subject, the method comprising:
administering to the subject a therapeutic to treat the subject based on identifying the subject as being positive for the sepsis state using the method of any one of claims 1-23, 25-30, or 31-35.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30)

A method of treating a sepsis state in a subject, the method comprising:
selecting a therapeutic to treat the subject based on determining that the subject is responsive to the therapeutic using the method of any of claims 1-23, 25-30, or 31-35; and
administering the selected therapeutic to the subject.

### Claim 42

A method for analyzing a set of peptide structures in a sample from a patient, the method comprising:
(a) preparing a sample from the patient to form a prepared sample comprising a set of peptide structures;
(b) inputting the prepared sample into a reaction monitoring mass spectrometry system to detect a set of product ions associated with each peptide structure of the set of peptide structures, the set of peptide structures comprising at least one of:
a first peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1386.1 within a range selected from a group consisting of ±1.0 and ±1.5;
a second peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1167.3 within a range selected from a group consisting of ±1.0 and ±1.5;
a third peptide structure associated with the corresponding set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1270.2 within a range selected from a group consisting of ±1.0 and ±1.5;
a fourth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1152.5 within a range selected from a group consisting of ±1.0 and ±1.5;
a fifth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 918.4 within a range selected from a group consisting of ±1.0 and ±1.5;
a sixth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1032.9 within a range selected from a group consisting of ±1.0 and ±1.5;
a seventh peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1197 within a range selected from a group consisting of ±1.0 and ±1.5;
an eighth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 984.4 within a range selected from a group consisting of ±1.0 and ±1.5;
a ninth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 874.7 within a range selected from a group consisting of ±1.0 and ±1.5;
a tenth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1225.8 within a range selected from a group consisting of ±1.0 and ±1.5;
an 11th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1073.4 within a range selected from a group consisting of ±1.0 and ±1.5;
a 12th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1183.5 within a range selected from a group consisting of ±1.0 and ±1.5;
a 13th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1015.2 within a range selected from a group consisting of ±1.0 and ±1.5;
a 14th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1284.6 within a range selected from a group consisting of ±1.0 and ±1.5;
a 15th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1039.1 within a range selected from a group consisting of ±1.0 and ±1.5;
a 16th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1285.1 within a range selected from a group consisting of ±1.0 and ±1.5;
a 17th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 1249.3±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1150.3 within a range selected from a group consisting of ±1.0 and ±1.5;
an 18th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1191.2 within a range selected from a group consisting of ±1.0 and ±1.5;
a 19th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1050.4 within a range selected from a group consisting of ±1.0 and ±1.5;
a 20th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 788.3 within a range selected from a group consisting of ±1.0 and ±1.5;
a 21st peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 878.8 within a range selected from a group consisting of ±1.0 and ±1.5;
a 22nd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 946.5 within a range selected from a group consisting of ±1.0 and ±1.5;
a 23rd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1281.5 within a range selected from a group consisting of ±1.0 and ±1.5;
a 24th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 873.4 within a range selected from a group consisting of ±1.0 and ±1.5;
a 25th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 922.1 within a range selected from a group consisting of ±1.0 and ±1.5;
a 26th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 764.8 within a range selected from a group consisting of ±1.0 and ±1.5;
a 27th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1087.1 within a range selected from a group consisting of ±1.0 and ±1.5;
a 28th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 976.1 within a range selected from a group consisting of ±1.0 and ±1.5;
a 29th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1073.1 within a range selected from a group consisting of ±1.0 and ±1.5;
a 30th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1043.8 within a range selected from a group consisting of ±1.0 and ±1.5;
a 31st peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 1009±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 891.8 within a range selected from a group consisting of ±1.0 and ±1.5;
a 32nd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 988.8 within a range selected from a group consisting of ±1.0 and ±1.5;
a 33rd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1142 within a range selected from a group consisting of ±1.0 and ±1.5;
a 34th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 911.4 within a range selected from a group consisting of ±1.0 and ±1.5;
a 35th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1041 within a range selected from a group consisting of ±1.0 and ±1.5;
a 36th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1008.2 within a range selected from a group consisting of ±1.0 and ±1.5;
a 37th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1109.8 within a range selected from a group consisting of ±1.0 and ±1.5;
a 38th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 761.7 within a range selected from a group consisting of ±1.0 and ±1.5;
a 39th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 939.1 within a range selected from a group consisting of ±1.0 and ±1.5;
a 40th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1206.3 within a range selected from a group consisting of ±1.0 and ±1.5;
a 41st structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 1199.2 within a range selected from a group consisting of ±1.0 and ±1.5;
a 42nd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 565.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 697.4 within a range selected from a group consisting of ±1.0 and ±1.5;
a 43rd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 736.4±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 618.3 within a range selected from a group consisting of ±1.0 and ±1.5;
a 44th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 342.2±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 590.3 within a range selected from a group consisting of ±1.0 and ±1.5;
a 45th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 342.2±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 590.3 within a range selected from a group consisting of ±1.0 and ±1.5; and
a 46th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 646.4±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio of 416.7 within a range selected from a group consisting of ±1.0 and ±1.5; and
(c) generating quantification data for the set of product ions using the reaction monitoring mass spectrometry system.

### Claim 43 (depends on 42)

The method of claim 42, further comprising, prior to (a), obtaining the sample from the patient.

### Claim 44 (depends on 42)

The method of claim 42, further comprising:
generating a diagnosis output using the quantification data and a model that has been trained using at least one of supervised or unsupervised machine learning.

### Claim 45 (depends on 42)

The method of claim 42, wherein the reaction monitoring mass spectrometry system uses or at least one of multiple reaction monitoring mass spectrometry (MRM-MS) or selected reaction monitoring mass spectrometry (SRM-MS) to detect the set of product ions and generate the quantification data.

### Claim 46 (depends on 42)

The method of claim 42, wherein the sample comprises a plasma sample.

### Claim 47 (depends on 42)

The method of claim 42, wherein the sample comprises a serum sample.

### Claim 48 (depends on 42)

The method of claim 42, wherein preparing the sample comprises at least one of:
denaturing one or more proteins in the sample using heat to form one or more denatured proteins;
reducing the one or more denatured proteins in the sample using a reducing agent to form one or more reduced proteins;
alkylating the one or more proteins in the sample using an alkylating agent to prevent reformation of disulfide bonds in the one or more reduced proteins to form one or more alkylated proteins; or
digesting the one or more alkylated proteins in the sample using a proteolysis catalyst to form the prepared sample comprising the set of peptide structures.

### Claim 49

A composition comprising at least one of peptide structures PS-1 to PS-46 identified in Table 1.

### Claim 50

A composition comprising a peptide structure or a product ion, wherein:
the peptide structure or product ion comprises an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NOS: 24-54, corresponding to peptide structures PS-1 to PS-46 in Table 1; and
the product ion is selected as one from a group consisting of product ions identified in Table 2 including product ions falling within an identified m/z range.

### Claim 51

A composition comprising a glycopeptide structure selected as one from a group of glycopeptide structures consisting of:
wherein:
a first glycopeptide structure having a monoisotopic mass of 5538.39 and comprising:
the amino acid sequence of SEQ ID NO: 24; and
glycan structure GL NO. 7601 linked to the 15th residue of SEQ ID NO: 24;
a second glycopeptide structure having a monoisotopic mass of 5829.49 and comprising:
the amino acid sequence of SEQ ID NO: 24; and
glycan structure GL NO. 7602 linked to the 15th residue of SEQ ID NO: 24;
a third glycopeptide structure having a monoisotopic mass of 3807.44 and comprising:
the amino acid sequence of SEQ ID NO: 25; and
glycan structure GL NO. 6503 linked to the 5th residue of SEQ ID NO: 25;
a fourth glycopeptide structure having a monoisotopic mass of 4603.94 and comprising: the amino acid sequence of SEQ ID NO: 26; and
glycan structure GL NO. 5412 linked to the 16th residue of SEQ ID NO: 26;
a fifth glycopeptide structure having a monoisotopic mass of 4584.93 and comprising:
the amino acid sequence of SEQ ID NO: 27; and
glycan structure GL NO. 5421 linked to the 2nd residue of SEQ ID NO: 27;
a sixth glycopeptide structure having a monoisotopic mass of 4125.73 and comprising:
the amino acid sequence of SEQ ID NO: 28; and
glycan structure GL NO. 5401 linked to the 3rd residue of SEQ ID NO: 28;
a seventh glycopeptide structure having a monoisotopic mass of 4781.95 and comprising:
the amino acid sequence of SEQ ID NO: 28; and
glycan structure GL NO. 6502 linked to the 3rd residue of SEQ ID NO: 28;
an eighth glycopeptide structure having a monoisotopic mass of 4915.03 and comprising:
the amino acid sequence of SEQ ID NO: 29; and
glycan structure GL NO. 5402 linked to the 8th residue of SEQ ID NO: 29;
a ninth glycopeptide structure having a monoisotopic mass of 2621.06 and comprising:
the amino acid sequence of SEQ ID NO: 30; and
glycan structure GL NO. 5301 linked to the 1st residue of SEQ ID NO: 30;
a tenth glycopeptide structure having a monoisotopic mass of 4900.17 and comprising:
the amino acid sequence of SEQ ID NO: 31; and
glycan structure GL NO. 6411 linked to the 6th residue of SEQ ID NO: 31;
an 11th glycopeptide structure having a monoisotopic mass of 4231.67 and comprising:
the amino acid sequence of SEQ ID NO: 32; and
glycan structure GL NO. 6610 linked to the 11th residue of SEQ ID NO: 32;
a 12th glycopeptide structure having a monoisotopic mass of 4729.04 and comprising:
the amino acid sequence of SEQ ID NO: 33; and
glycan structure GL NO. 7602 linked to the 6th residue of SEQ ID NO: 33;
a 13th glycopeptide structure having a monoisotopic mass of 4055.56 and comprising:
the amino acid sequence of SEQ ID NO: 34; and
glycan structure GL NO. 5402 linked to the 1st or 7th residue of SEQ ID NO: 34;
a 14th glycopeptide structure having a monoisotopic mass of 5133.19 and comprising:
the amino acid sequence of SEQ ID NO: 34; and
glycan structure GL NO. 5402 linked to the 7th residue of SEQ ID NO: 34;
a 15th glycopeptide structure having a monoisotopic mass of 5191.23 and comprising:
comprising the amino acid sequence of SEQ ID NO: 35; and
glycan structure GL NO. 5402 linked to the 19th residue of SEQ ID NO: 35;
a 16th glycopeptide structure having a monoisotopic mass of 5133.19 and comprising:
comprising the amino acid sequence of SEQ ID NO: 35; and
glycan structure GL NO. 5511 linked to the 19th residue of SEQ ID NO: 35;
a 17th glycopeptide structure having a monoisotopic mass of 5744.60 and comprising:
the amino acid sequence of SEQ ID NO: 35; and
glycan structure GL NO. 5402 linked to the 19th residue of SEQ ID NO: 35;
a 18th glycopeptide structure having a monoisotopic mass of 4758.93 and comprising:
the amino acid sequence of SEQ ID NO: 36; and
glycan structure GL NO. 5402 linked to the 4th residue of SEQ ID NO: 36;
a 19th glycopeptide structure having a monoisotopic mass of 3148.20 and comprising:
the amino acid sequence of SEQ ID NO: 37; and
glycan structure GL NO. 6513 linked to the 4th residue of SEQ ID NO: 37;
a 20th glycopeptide structure having a monoisotopic mass of 3148.20 and comprising:
the amino acid sequence of SEQ ID NO: 38; and
glycan structure GL NO. 5402 linked to the 2nd residue of SEQ ID NO: 38;
a 21st glycopeptide structure having a monoisotopic mass of 2633.04 and comprising:
the amino acid sequence of SEQ ID NO: 39; and
glycan structure GL NO. 3410 linked to the 5th residue of SEQ ID NO: 39;
a 22nd glycopeptide structure having a monoisotopic mass of 2836.12 and comprising:
the amino acid sequence of SEQ ID NO: 39; and
glycan structure GL NO. 3510 linked to the 5th residue of SEQ ID NO: 39;
a 23rd glycopeptide structure having a monoisotopic mass of 2560.02 and comprising:
the amino acid sequence of SEQ ID NO: 39; and
glycan structure GL NO. 4310 linked to the 5th residue of SEQ ID NO: 39;
a 24th glycopeptide structure having a monoisotopic mass of 2617.04 and comprising:
the amino acid sequence of SEQ ID NO: 39; and
glycan structure GL NO. 4400 linked to the 5th residue of SEQ ID NO: 39;
a 25th glycopeptide structure having a monoisotopic mass of 2763.10 and comprising:
the amino acid sequence of SEQ ID NO: 39; and
glycan structure GL NO. 4410 linked to the 5th residue of SEQ ID NO: 39;
a 26th glycopeptide structure having a monoisotopic mass of 3054.20 and comprising:
the amino acid sequence of SEQ ID NO: 39; and
glycan structure GL NO. 4411 linked to the 5th residue of SEQ ID NO: 39;
a 27th glycopeptide structure having a monoisotopic mass of 3257.28 and comprising:
the amino acid sequence of SEQ ID NO: 39; and
glycan structure GL NO. 4511 linked to the 5th residue of SEQ ID NO: 39;
a 28th glycopeptide structure having a monoisotopic mass of 2925.15 and comprising:
the amino acid sequence of SEQ ID NO: 39; and
glycan structure GL NO. 5410 linked to the 5th residue of SEQ ID NO: 39;
a 29th glycopeptide structure having a monoisotopic mass of 3216.25 and comprising:
the amino acid sequence of SEQ ID NO: 39; and
glycan structure GL NO. 5411 linked to the 5th residue of SEQ ID NO: 39;
a 30th glycopeptide structure having a monoisotopic mass of 3128.23 and comprising:
the amino acid sequence of SEQ ID NO: 39; and
glycan structure GL NO. 5510 linked to the 5th residue of SEQ ID NO: 39;
a 31st glycopeptide structure having a monoisotopic mass of 2671.29 and comprising:
the amino acid sequence of SEQ ID NO: 40; and
glycan structure GL NO. 1101 linked to the 6th residue of SEQ ID NO: 40;
a 32nd glycopeptide structure having a monoisotopic mass of 2962.39 and comprising:
the amino acid sequence of SEQ ID NO: 40; and
glycan structure GL NO. 1102 linked to the 6th residue of SEQ ID NO: 40;
a 33rd glycopeptide structure having a monoisotopic mass of 4561.95 and comprising:
the amino acid sequence of SEQ ID NO: 41; and
glycan structure GL NO. 5402 linked to the 6th residue of SEQ ID NO: 41;
a 34th glycopeptide structure having a monoisotopic mass of 3640.56 and comprising:
the amino acid sequence of SEQ ID NO: 42; and
glycan structure GL NO. 5402 linked to the 7th residue of SEQ ID NO: 42;
a 35th glycopeptide structure having a monoisotopic mass of 4159.85 and comprising:
the amino acid sequence of SEQ ID NO: 43; and
glycan structure GL NO. 5401 linked to the 6th residue of SEQ ID NO: 43;
a 36th glycopeptide structure having a monoisotopic mass of 5034.18 and comprising:
the amino acid sequence of SEQ ID NO: 44; and
glycan structure GL NO. 5402 linked to the 2nd residue of SEQ ID NO: 44;
a 37th glycopeptide structure having a monoisotopic mass of 3326.42 and comprising:
the amino acid sequence of SEQ ID NO: 45; and
glycan structure GL NO. 6301 linked to the 10th residue of SEQ ID NO: 45;
a 38th glycopeptide structure having a monoisotopic mass of 2280.98 and comprising:
the amino acid sequence of SEQ ID NO: 46; and
glycan structure GL NO. 1102 linked to the 8th residue of SEQ ID NO: 46;
a 39th glycopeptide structure having a monoisotopic mass of 2813.31 and comprising:
the amino acid sequence of SEQ ID NO: 47; and
glycan structure GL NO. 1101 linked to the 12th residue of SEQ ID NO: 47;
a 40th glycopeptide structure having a monoisotopic mass of 8432.83 and comprising:
the amino acid sequence of SEQ ID NO: 48; and
glycan structure GL NO. 5402 linked to the 46th residue of SEQ ID NO: 48;
a 41st glycopeptide structure having a monoisotopic mass of 4791.91 and comprising:
the amino acid sequence of SEQ ID NO: 49; and
glycan structure GL NO. 7420 linked to the 4th residue of SEQ ID NO: 49;
wherein:
the glycan structure GL NO. 1101 comprises:
the glycan structure GL NO. 1102 comprises:
the glycan structure GL NO. 3410 comprises:
the glycan structure GL NO. 3510 comprises:
the glycan structure GL NO. 3510 comprises:
the glycan structure GL NO. 4310 comprises:
the glycan structure GL NO. 4400 comprises:
the glycan structure GL NO. 4410 comprises:
the glycan structure GL NO. 4411 comprises:
the glycan structure GL NO. 4511 comprises:
the glycan structure GL NO. 5301 comprises:
the glycan structure GL NO. 5401 comprises:
the glycan structure GL NO. 5402 comprises:
the glycan structure GL NO. 5410 comprises:
the glycan structure GL NO. 5411 comprises:
the glycan structure GL NO. 5412 comprises:
the glycan structure GL NO. 5421 comprises:
the glycan structure GL NO. 5510 comprises:
the glycan structure GL NO. 5511 comprises:
the glycan structure GL NO. 5511 comprises:
the glycan structure GL NO. 6301 comprises:
the glycan structure GL NO. 6411 comprises:
the glycan structure GL NO. 6502 comprises:
the glycan structure GL NO. 6503 comprises:
the glycan structure GL NO. 6513 comprises:
the glycan structure GL NO. 6610 comprises:
the glycan structure GL NO. 7420 comprises:
the glycan structure GL NO. 7602 comprises:
and
the glycan structure GL NO. 7601 comprises:

### Claim 52 (depends on 51)

The composition of claim 51, wherein:
the first glycopeptide structure has a precursor ion having a charge of 4;
the second glycopeptide structure has a precursor ion having a charge of 5;
the third glycopeptide structure has a precursor ion having a charge of 3;
the fourth glycopeptide structure has a precursor ion having a charge of 4;
the fifth glycopeptide structure has a precursor ion having a charge of 5;
the sixth glycopeptide structure has a precursor ion having a charge of 4;
the seventh glycopeptide structure has a precursor ion having a charge of 4;
the eighth glycopeptide structure has a precursor ion having a charge of 5;
the ninth glycopeptide structure has a precursor ion having a charge of 3;
the tenth glycopeptide structure has a precursor ion having a charge of 4;
the 11th glycopeptide structure has a precursor ion having a charge of 4;
the 12th glycopeptide structure has a precursor ion having a charge of 4;
the 13th glycopeptide structure has a precursor ion having a charge of 4;
the 14th glycopeptide structure has a precursor ion having a charge of 4;
the 15th glycopeptide structure has a precursor ion having a charge of 5;
the 16th glycopeptide structure has a precursor ion having a charge of 4;
the 17th glycopeptide structure has a precursor ion having a charge of 5;
the 18th glycopeptide structure has a precursor ion having a charge of 4;
the 19th glycopeptide structure has a precursor ion having a charge of 3;
the 20th glycopeptide structure has a precursor ion having a charge of 4;
the 21st glycopeptide structure has a precursor ion having a charge of 3;
the 22nd glycopeptide structure has a precursor ion having a charge of 3;
the 23rd glycopeptide structure has a precursor ion having a charge of 2;
the 24th glycopeptide structure has a precursor ion having a charge of 3;
the 25th glycopeptide structure has a precursor ion having a charge of 3;
the 26th glycopeptide structure has a precursor ion having a charge of 4;
the 27th glycopeptide structure has a precursor ion having a charge of 3;
the 28th glycopeptide structure has a precursor ion having a charge of 3;
the 29th glycopeptide structure has a precursor ion having a charge of 3;
the 30th glycopeptide structure has a precursor ion having a charge of 3;
the 31st glycopeptide structure has a precursor ion having a charge of 3;
the 32nd glycopeptide structure has a precursor ion having a charge of 3;
the 33rd glycopeptide structure has a precursor ion having a charge of 4;
the 34th glycopeptide structure has a precursor ion having a charge of 4;
the 35th glycopeptide structure has a precursor ion having a charge of 4;
the 36th glycopeptide structure has a precursor ion having a charge of 5;
the 37th glycopeptide structure has a precursor ion having a charge of 3;
the 38th glycopeptide structure has a precursor ion having a charge of 3;
the 39th glycopeptide structure has a precursor ion having a charge of 3;
the 40th glycopeptide structure has a precursor ion having a charge of 7; and
the 41st glycopeptide structure has a precursor ion having a charge of 4.

### Claim 53 (depends on 51, 52)

The composition of claim 51 or claim 52, wherein:
the first glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the second glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the third glycopeptide structure associated with the corresponding set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the fourth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0;
the fifth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the sixth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the seventh glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the eighth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0;
the ninth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the tenth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 11th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 12th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 13th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 14th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 15th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 16th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 17th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 1249.3±0.5, ±0.8, and ±1.0;
the 18th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 19th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 20th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 21st glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0;
the 22nd glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0;
the 23rd glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 24th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0;
the 25th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0;
the 26th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0;
the 27th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0;
the 28th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 29th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 30th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 31st glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 1009±0.5, ±0.8, and ±1.0;
the 32nd glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0;
the 33rd glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0;
the 34th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0;
the 35th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 36th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 37th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 38th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0;
the 39th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0;
the 40th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0; and
the 41st glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0.

### Claim 54 (depends on 51, 52, 53)

The composition of any one of claims 51-53, wherein:
the first glycopeptide structure has a precursor ion having an m/z ratio of 1386.1 within a range selected from a group consisting of ±1.0 and ±1.5;
the second glycopeptide structure has a precursor ion having an m/z ratio of 1167.3 within a range selected from a group consisting of ±1.0 and ±1.5;
the third glycopeptide structure has a precursor ion having an m/z ratio of 1270.2 within a range selected from a group consisting of ±1.0 and ±1.5;
the fourth glycopeptide structure has a precursor ion having an m/z ratio of 1152.5 within a range selected from a group consisting of ±1.0 and ±1.5;
the fifth glycopeptide structure has a precursor ion having an m/z ratio of 918.4 within a range selected from a group consisting of ±1.0 and ±1.5;
the sixth glycopeptide structure has a precursor ion having an m/z ratio of 1032.9 within a range selected from a group consisting of ±1.0 and ±1.5;
the seventh glycopeptide structure has a precursor ion having an m/z ratio of 1197 within a range selected from a group consisting of ±1.0 and ±1.5;
the eighth glycopeptide structure has a precursor ion having an m/z ratio of 984.4 within a range selected from a group consisting of ±1.0 and ±1.5;
the ninth glycopeptide structure has a precursor ion having an m/z ratio of 874.7 within a range selected from a group consisting of ±1.0 and ±1.5;
the tenth glycopeptide structure has a precursor ion having an m/z ratio of 1225.8 within a range selected from a group consisting of ±1.0 and ±1.5;
the 11th glycopeptide structure has a precursor ion having an m/z ratio of 1073.4 within a range selected from a group consisting of ±1.0 and ±1.5;
the 12th glycopeptide structure has a precursor ion having an m/z ratio of 1183.5 within a range selected from a group consisting of ±1.0 and ±1.5;
the 13th glycopeptide structure has a precursor ion having an m/z ratio of 1015.2 within a range selected from a group consisting of ±1.0 and ±1.5;
the 14th glycopeptide structure has a precursor ion having an m/z ratio of 1284.6 within a range selected from a group consisting of ±1.0 and ±1.5;
the 15th glycopeptide structure has a precursor ion having an m/z ratio of 1039.1 within a range selected from a group consisting of ±1.0 and ±1.5;
the 16th glycopeptide structure has a precursor ion having an m/z ratio of 1285.1 within a range selected from a group consisting of ±1.0 and ±1.5;
the 17th glycopeptide structure has a precursor ion having an m/z ratio of 1150.3 within a range selected from a group consisting of ±1.0 and ±1.5;
the 18th glycopeptide structure has a precursor ion having an m/z ratio of 1191.2 within a range selected from a group consisting of ±1.0 and ±1.5;
the 19th glycopeptide structure has a precursor ion having an m/z ratio of 1050.4 within a range selected from a group consisting of ±1.0 and ±1.5;
the 20th glycopeptide structure has a precursor ion having an m/z ratio of 788.3 within a range selected from a group consisting of ±1.0 and ±1.5;
the 21st glycopeptide structure has a precursor ion having an m/z ratio of 878.8 within a range selected from a group consisting of ±1.0 and ±1.5;
the 22nd glycopeptide structure has a precursor ion having an m/z ratio of 946.5 within a range selected from a group consisting of ±1.0 and ±1.5;
the 23rd glycopeptide structure has a precursor ion having an m/z ratio of 1281.5 within a range selected from a group consisting of ±1.0 and ±1.5;
the 24th glycopeptide structure has a precursor ion having an m/z ratio of 873.4 within a range selected from a group consisting of ±1.0 and ±1.5;
the 25th glycopeptide structure has a precursor ion having an m/z ratio of 922.1 within a range selected from a group consisting of ±1.0 and ±1.5;
the 26th glycopeptide structure has a precursor ion having an m/z ratio of 764.8 within a range selected from a group consisting of ±1.0 and ±1.5;
the 27th glycopeptide structure has a precursor ion having an m/z ratio of 1087.1 within a range selected from a group consisting of ±1.0 and ±1.5;
the 28th glycopeptide structure has a precursor ion having an m/z ratio of 976.1 within a range selected from a group consisting of ±1.0 and ±1.5;
the 29th glycopeptide structure has a precursor ion having an m/z ratio of 1073.1 within a range selected from a group consisting of ±1.0 and ±1.5;
the 30th glycopeptide structure has a precursor ion having an m/z ratio of 1043.8 within a range selected from a group consisting of ±1.0 and ±1.5;
the 31st glycopeptide structure has a precursor ion having an m/z ratio of 891.8 within a range selected from a group consisting of ±1.0 and ±1.5;
the 32nd glycopeptide structure has a precursor ion having an m/z ratio of 988.8 within a range selected from a group consisting of ±1.0 and ±1.5;
the 33rd glycopeptide structure has a precursor ion having an m/z ratio of 1142 within a range selected from a group consisting of ±1.0 and ±1.5;
the 34th glycopeptide structure has a precursor ion having an m/z ratio of 911.4 within a range selected from a group consisting of ±1.0 and ±1.5;
the 35th glycopeptide structure has a precursor ion having an m/z ratio of 1041 within a range selected from a group consisting of ±1.0 and ±1.5;
the 36th glycopeptide structure has a precursor ion having an m/z ratio of 1008.2 within a range selected from a group consisting of ±1.0 and ±1.5;
the 37th glycopeptide structure has a precursor ion having an m/z ratio of 1109.8 within a range selected from a group consisting of ±1.0 and ±1.5;
the 38th glycopeptide structure has a precursor ion having an m/z ratio of 761.7 within a range selected from a group consisting of ±1.0 and ±1.5;
the 39th glycopeptide structure has a precursor ion having an m/z ratio of 939.1 within a range selected from a group consisting of ±1.0 and ±1.5;
the 40th glycopeptide structure has a precursor ion having an m/z ratio of 1206.3 within a range selected from a group consisting of ±1.0 and ±1.5; and
the 41st structure has a precursor ion having an m/z ratio of 1199.2 within a range selected from a group consisting of ±1.0 and ±1.5.

### Claim 55

A composition comprising a peptide structure selected as one from a group of aglycosylated peptide structures consisting of:
a first peptide structure having a monoisotopic mass of 1392.69 and comprising the amino acid sequence of SEQ ID NO: 50;
a second peptide structure having a monoisotopic mass of 1234.68 and comprising the amino acid sequence of SEQ ID NO: 51;
a third peptide structure having a monoisotopic mass of 1178.67 and comprising the amino acid sequence of SEQ ID NO: 52;
a fourth peptide structure having a monoisotopic mass of 2454.14 and comprising the amino acid sequence of SEQ ID NO: 53; and
a fifth peptide structure having a monoisotopic mass of 831.47 and comprising the amino acid sequence of SEQ ID NO: 54.

### Claim 56 (depends on 55)

The composition of claim 55, wherein:
the first peptide structure has a precursor ion having a charge of 2;
the second peptide structure has a precursor ion having a charge of 2;
the third peptide structure has a precursor ion having a charge of 2;
the fourth peptide structure has a precursor ion having a charge of 3; and
the fifth peptide structure has a precursor ion having a charge of 2.

### Claim 57 (depends on 55, 56)

The composition of claim 55 or 56, wherein:
the first peptide structure has a precursor ion m/z ratio within a range selected from a group consisting of 697.4+/−1.0, and +/−1.5;
the second peptide structure has a precursor ion m/z ratio within a range selected from a group consisting of 618.3+/−1.0, and +/−1.5;
the third peptide structure has a precursor ion m/z ratio within a range selected from a group consisting of 590.3+/−1.0, and +/−1.5;
the fourth peptide structure has a precursor ion m/z ratio within a range selected from a group consisting of 819.1+/−1.0, and +/−1.5; and
the fifth peptide structure has a precursor ion m/z ratio within a range selected from a group consisting of 416.7+/−1.0, and +/−1.5.

### Claim 58 (depends on 55, 56)

The composition of claim 55 or 56, wherein:
the first peptide structure has a product ion m/z ratio within a range selected from a group consisting of 565.3+/−0.5, +/−0.8, and +/−1.0;
the second peptide structure has a product ion m/z ratio within a range selected from a group consisting of 736.4+/−0.5, +/−0.8, and +/−1.0;
the third peptide structure has a product ion m/z ratio within a range selected from a group consisting of 342.2+/−0.5, +/−0.8, and +/−1.0;
the fourth peptide structure has a product ion m/z ratio within a range selected from a group consisting of 609.3+/−0.5, +/−0.8, and +/−1.0; and
the fifth peptide structure has a product ion m/z ratio within a range selected from a group consisting of 646.4+/−0.5, +/−0.8, and +/−1.0.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A kit comprising at least one agent for quantifying at least one peptide structure identified in Table 1 to carry out the method of any one of claims 1-48.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A kit comprising at least one of a glycopeptide standard, a buffer, or a set of peptide sequences to carry out the method of any one of claims 1-48, a peptide sequence of the set of peptide sequences identified by a corresponding one of SEQ ID NOS: 24-54, defined in Table 3.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30)

A system comprising:
one or more data processors; and
a non-transitory computer readable storage medium containing instructions which, when executed on the one or more data processors, cause the one or more data processors to perform part or all of any one of claims 1-23, 25-30, or 31-35.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, 29, 30)

A computer-program product tangibly embodied in a non-transitory machine-readable storage medium, including instructions configured to cause one or more data processors to perform part or all of any one of claims 1-23, 25-30, or 31-35.

### Claim 63

A method of determining whether a biological sample corresponds to a symptomatic disease state of a coronavirus disease (COVID), the method comprising:
inputting quantification data identified from peptide structure data for a set of peptide structures into a supervised machine learning model, wherein the set of peptide structures includes at least one peptide structure identified in Table 2-1;
analyzing the quantification data using the supervised machine learning model to generate a disease indicator that classifies the biological sample as corresponding to a cluster of a plurality of clusters that has a least distance to the biological sample, the plurality of clusters corresponding a plurality of states that includes the symptomatic disease state; and
generating a diagnosis output based on the disease indicator.

### Claim 64 (depends on 63)

The method of claim 63, further comprising receiving peptide structure data corresponding to the biological sample obtained from a subject.

### Claim 65 (depends on 63)

The method of claim 63, wherein the at least one peptide structure comprises a glycopeptide structure defined by a peptide sequence and a glycan structure linked to the peptide sequence at a linking site of the peptide sequence, as identified in Table 2-1, with the peptide sequence being one of SEQ ID NOS: 84-116 as defined in Table 5-1.

### Claim 66 (depends on 63)

The method of claim 63, wherein the at least one peptide structure comprises an aglycosylated peptide structure defined by a peptide sequence, as identified in Table 2-1, with the peptide sequence being one of SEQ ID NOS: 107-110 as defined in Table 5-1.

### Claim 67 (depends on 63)

The method of claim 63, wherein the supervised machine learning model comprises a Support Vector Machine (SVM) classifier.

### Claim 68 (depends on 63)

The method of claim 63, wherein the supervised machine learning model comprises at least one of a Support Vector Machine (SVM) classifier, a Support Vector Classifier (SVC) model, a linear classifier, a decision tree, a random forest algorithm, a k-Nearest Neighbors algorithm, a Naive Bayes algorithm, or a gradient boosting algorithm.

### Claim 69 (depends on 63)

The method of claim 63, further comprising:
training the supervised machine learning model using training data generated from an unsupervised machine learning model,
wherein the training data comprises a plurality of peptide structure profiles for a plurality of subjects and identifies a corresponding state of the plurality of states for each peptide structure profile of the plurality of peptide structure profiles; and
wherein the unsupervised machine learning model is trained to cluster the plurality of peptide structure profiles into the plurality of clusters.

### Claim 70 (depends on 69)

The method of claim 69, wherein the unsupervised machine learning model is a k-means clustering model.

### Claim 71 (depends on 69)

The method of claim 69, wherein a peptide structure profile of the plurality of peptide structure profiles for a corresponding subject of the plurality of subjects is selected based on a differential expression analysis of quantification metrics for a panel of peptide structures for the plurality of subjects.

### Claim 72 (depends on 71)

The method of claim 71, further comprising:
comparing, using the differential expression analysis, the quantification metrics corresponding to the panel of peptide structures for a first portion of the plurality of subjects diagnosed with the symptomatic disease state to that of each portion of a set of other portions of the plurality of subjects to generate a set of comparisons; and
selecting a portion of the panel of peptide structures having a false discovery rate below 0.05 across the set of comparisons as the set of peptide structures.

### Claim 73 (depends on 72)

The method of claim 72, wherein the comparing comprises:
comparing the quantification metrics corresponding to the panel of peptide structures for the first portion of the plurality of subjects diagnosed with the symptomatic disease state to that of a second portion of the plurality of subjects diagnosed with a sepsis state to generate a first comparison of the set of comparisons.

### Claim 74 (depends on 73)

The method of claim 73, wherein the comparing further comprises:
comparing the quantification metrics corresponding to the panel of peptide structures for the first portion of the plurality of subjects diagnosed with the symptomatic disease state to that of at least one of:
a third portion of the plurality of subjects diagnosed with a common cold state to generate a second comparison of the set of comparisons;
a third portion of the plurality of subjects diagnosed with an asymptomatic disease state of the coronavirus disease to generate a third comparison of the set of comparisons; or
a fourth portion of the plurality of subjects diagnosed with a healthy state to generate a fourth comparison of the set of comparisons.

### Claim 75 (depends on 63)

The method of claim 63, wherein the quantification data for a peptide structure of the set of peptide structures comprises at least one of a relative quantity, an adjusted quantity, a normalized quantity, a relative concentration, an adjusted concentration, or a normalized concentration.

### Claim 76 (depends on 63)

The method of claim 63, wherein the peptide structure data is generated using multiple reaction monitoring mass spectrometry (MRM-MS).

### Claim 77 (depends on 63)

The method of claim 63, further comprising:
creating a sample from the biological sample; and
preparing the sample using reduction, alkylation, and enzymatic digestion to form a prepared sample that includes a set of peptide structures.

### Claim 78 (depends on 63)

The method of claim 63, further comprising:
generating the peptide structure data from the prepared sample using multiple reaction monitoring mass spectrometry (MRM-MS).

### Claim 79 (depends on 63)

The method of claim 63, wherein generating the diagnosis output comprises:
generating a report that includes a diagnosis that the subject is positive for the symptomatic disease state in response to the disease indicator classifying the biological sample as corresponding to the symptomatic disease state of the coronavirus disease.

### Claim 80 (depends on 63)

The method of claim 63, wherein the coronavirus disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

### Claim 81 (depends on 63)

The method of claim 63, further comprising:
generating a treatment output based on at least one of the diagnosis output or the disease indicator.

### Claim 82 (depends on 81)

The method of claim 81, wherein the treatment output comprises at least one of an identification of a treatment to treat the subject, a design for the treatment, a manufacturing plan for the treatment, or a treatment plan for administering the treatment.

### Claim 83 (depends on 81)

The method of claim 81, wherein the treatment comprises at least one of an antiviral therapeutic, an anti-inflammatory therapeutic, or an immune-based therapeutic.

### Claim 84 (depends on 81)

The method of claim 81, wherein the treatment comprises at least one of remdesivir, baricitinib, tocilizumab, favipiravir, merimepodib, a monoclonal antibody therapeutic, Nirmatrelvir with Ritonavi, Molnupiravir, and/or an immune checkpoint inhibitor.

### Claim 85 (depends on 81)

The method of claim 81, wherein generating the treatment output comprises:
determining a dosage for a therapeutic to treat the subject based on at least one of the diagnosis output or the disease indicator.

### Claim 86 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The method of any one of claims 63-85, wherein the diagnosis output identifies that the biological sample is positive for the symptomatic disease state and further comprising:
administering a therapeutic dosage of a therapeutic for the coronavirus disease to the subject, the therapeutic being selected from the group consisting of remdesivir, baricitinib, tocilizumab, favipiravir, merimepodib, a monoclonal antibody treatment, Nirmatrelvir with Ritonavi, Molnupiravir, and/or an immune checkpoint inhibitor.

### Claim 87

A method of identifying a coronavirus disease (COVID)-specific set of peptide structures for use in diagnosing a symptomatic disease state of the coronavirus disease, the method comprising:
receiving quantification data for a panel of peptide structures for a plurality of subjects diagnosed with a plurality of states, the plurality of states including the symptomatic disease state of the coronavirus disease;
comparing quantification metrics corresponding to the panel of peptide structures for a first portion of the plurality of subjects diagnosed with the symptomatic disease state to that of each portion of a set of other portions of the plurality of subjects to generate a set of comparisons using a differential expression analysis;
selecting a portion of the panel of peptide structures having a false discovery rate below 0.05 across the set of comparisons as a set of peptide structures to be associated with the coronavirus disease,
wherein the set of peptide structures includes at least one glycopeptide structure defined by a peptide sequence and a glycan structure linked to the peptide sequence at a linking site of the peptide sequence;
analyzing the quantification data for the set of peptide structures for the plurality of subjects using an unsupervised machine learning model to cluster the plurality of subjects; and
training a supervised machine learning model to determine whether a biological sample obtained from a subject corresponds to the symptomatic disease state or another state of the plurality of states.

### Claim 88 (depends on 87)

The method of claim 87, further comprising:
analyzing the biological sample obtained from the subject using the supervised machine learning model that has been trained to generate a disease indicator that indicates whether the biological subject is positive for the symptomatic disease state.

### Claim 89 (depends on 87)

The method of claim 87, wherein the plurality of states further includes at least one of a sepsis state, a common cold state, a healthy state, or an asymptomatic disease state of the coronavirus disease.

### Claim 90 (depends on 87)

The method of claim 87, wherein the coronavirus disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

### Claim 91 (depends on 87)

The method of claim 87, wherein the unsupervised machine learning model comprises a k-means clustering model and wherein the supervised machine learning model comprises at least one of a Support Vector Machine (SVM) classifier, a Support Vector Classifier (SVC) model, a linear classifier, a decision tree, a random forest algorithm, a k-Nearest Neighbors algorithm, a Naive Bayes algorithm, or a gradient boosting algorithm.

### Claim 92 (depends on 87)

The method of claim 87, wherein the set of peptide structures includes at least three peptide structures identified in Table 2-1.

### Claim 93

A method of diagnosing a symptomatic disease state of a coronavirus disease (COVID), the method comprising:
analyzing peptide structure data using a supervised machine learning model to generate a disease indicator that indicates whether a biological sample is positive for the symptomatic disease state based on at least 3 peptide structures selected from a group of peptide structures identified in Table 3-1,
wherein the group of peptide structures in Table 3-1 comprises a group of peptide structures associated with the symptomatic disease state; and
wherein the group of peptide structures is listed in Table 3-1 with respect to relative significance to the disease indicator; and
generating a diagnosis output based on the disease indicator.

### Claim 94 (depends on 93)

The method of claim 93, further comprising receiving peptide structure data corresponding to a biological sample obtained from a subject.

### Claim 95 (depends on 93)

The method of claim 93, wherein a peptide structure of the at least 3 peptide structures comprises a glycopeptide structure defined by a peptide sequence and a glycan structure linked to the peptide sequence at a linking site of the peptide sequence, as identified in Table 3-1, with the peptide sequence, which is one of SEQ ID NOS: 84, 85, 92, 94, 96, 97, 104 and 111-116, being defined in Table 5-1.

### Claim 96 (depends on 93)

The method of claim 93, wherein a peptide structure of the at least 3 peptide structures comprises an aglycosylated peptide structure defined by a peptide sequence, as identified in Table 3-1, with the peptide sequence, which is one of SEQ ID NOS: 107-110, being defined in Table 5-1.

### Claim 97 (depends on 93)

The method of claim 93, wherein the at least 3 peptide structures includes 16 glycopeptide structures and 2 aglycosylated peptide structures.

### Claim 98 (depends on 93)

The method of claim 93, wherein the supervised machine learning model comprises a regression model.

### Claim 99 (depends on 93)

The method of claim 93, wherein the supervised machine learning model comprises a penalized multivariable regression model.

### Claim 100 (depends on 93)

The method of claim 93, wherein the peptide structure data comprises quantification data for each peptide structure of a panel of peptide structures, the panel of peptide structures including the at least 3 peptide structures.

### Claim 101 (depends on 100)

The method of claim 100, wherein the quantification data for a peptide structure of the plurality of peptide structures comprises at least one of a relative quantity, an adjusted quantity, a normalized quantity, a relative concentration, an adjusted concentration, or a normalized concentration.

### Claim 102 (depends on 93)

The method of claim 93, wherein the disease indicator comprises at least one of a probability that the subject is positive for the symptomatic disease state, an odds that the subject is positive for the symptomatic disease state, a logarithm of the odds that the subject is positive for the symptomatic disease state, or a classification of the biological sample as either positive or negative for the symptomatic disease state.

### Claim 103 (depends on 93)

The method of claim 93, wherein generating the diagnosis output comprises:
generating a report that includes a diagnosis that the subject is positive for the symptomatic disease state in response to a determination that the disease indicator is above a selected threshold.

### Claim 104 (depends on 103)

The method of claim 103, wherein the selected threshold comprises at least one a probability threshold selected as a value between a range from 0.50 to 0.95 or a logit threshold selected as a value either equal to or above 0.0.

### Claim 105 (depends on 93)

The method of claim 93, wherein analyzing the peptide structure data comprises:
computing the disease indicator using a weight coefficient associated with each peptide structure of the at least 3 peptide structures, the weight coefficient of a corresponding peptide structure of the at least 3 peptide structures indicating the relative significance of the corresponding peptide structure to the disease indicator.

### Claim 106 (depends on 93)

The method of claim 93, wherein analyzing the peptide structure data comprises:
computing a peptide structure profile for the biological sample that identifies a weighted value for each peptide structure of the at least 3 peptide structures, wherein the weighted value for a peptide structure of the at least 3 peptide structures is a product of a quantification metric for the peptide structure identified from the peptide structure data and a weight coefficient for the peptide structure; and
computing the disease indicator using the peptide structure profile.

### Claim 107 (depends on 93)

The method of claim 93, wherein the disease indicator comprises a probability that the biological sample is positive for the symptomatic disease state and wherein the supervised machine learning model is configured to generate an output that identifies the biological sample as either positive for the symptomatic disease state when the disease indicator is greater than a selected threshold or negative for the symptomatic disease state when the disease indicator is not greater than the selected threshold.

### Claim 108 (depends on 107)

The method of claim 107, wherein the selected threshold is a value selected as either equal to or above 0.5.

### Claim 109 (depends on 107)

The method of claim 107, wherein the selected threshold is a value within ±0.02 of 0.525.

### Claim 110 (depends on 93)

The method of claim 93, wherein:
the supervised machine learning model is trained to determine weight coefficients for a panel of peptide structures such that a first portion of the weight coefficients for a first portion of the panel of peptide structures are non-zero and a second portion of the weight coefficients for a second portion of the panel of peptide structures are zero; and
the first portion of the panel of peptide structures forms the group of peptide structures identified in Table 3-1.

### Claim 111 (depends on 110)

The method of claim 110, further comprising:
training the supervised machine learning model using training data that comprises a plurality of peptide structure profiles for a plurality of subjects and a corresponding state of a plurality of states for each peptide structure profile of the plurality of peptide structure profiles,
wherein the plurality of subjects includes a first portion diagnosed with the symptomatic disease state and at least one of:
a second portion having a healthy state;
a third portion diagnosed with a common cold state;
a fourth portion diagnosed with an asymptomatic disease state of the coronavirus disease (COVID); or
a fifth portion diagnosed with a sepsis state.

### Claim 112 (depends on 93)

The method of claim 93, wherein the symptomatic disease state is one of a plurality of symptomatic disease states for the coronavirus (COVID), the plurality of symptomatic disease states corresponding to varying levels of severity.

### Claim 113 (depends on 93)

The method of claim 93, further comprising:
creating a sample from the biological sample; and
preparing the sample using reduction, alkylation, and enzymatic digestion to form a prepared sample that includes a set of peptide structures.

### Claim 114 (depends on 113)

The method of claim 113, further comprising:
generating the peptide structure data from the prepared sample using multiple reaction monitoring mass spectrometry (MRM-MS).

### Claim 115 (depends on 93)

The method of claim 93, wherein the coronavirus disease (COVID) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

### Claim 116 (depends on 93)

The method of claim 93, further comprising:
generating a treatment output based on at least one of the diagnosis output or the disease indicator.

### Claim 117 (depends on 116)

The method of claim 116, wherein the treatment output comprises at least one of an identification of a treatment to treat the subject, a design for the treatment, a manufacturing plan for the treatment, or a treatment plan for administering the treatment.

### Claim 118 (depends on 116)

The method of claim 116, wherein the treatment comprises at least one of an antiviral therapeutic, an anti-inflammatory therapeutic, or an immune-based therapeutic.

### Claim 119 (depends on 116)

The method of claim 116, wherein the treatment comprises at least one of remdesivir, baricitinib, tocilizumab, favipiravir, merimepodib, a monoclonal antibody therapeutic, Nirmatrelvir with Ritonavi, Molnupiravir, and/or an immune checkpoint inhibitor.

### Claim 120 (depends on 116)

The method of claim 116, wherein generating the treatment output comprises:
determining a dosage for a therapeutic to treat the subject based on at least one of the diagnosis output or the disease indicator.

### Claim 121 (depends on 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

The method of any one of claims 93-120, wherein the diagnosis output identifies that the biological sample is positive for the symptomatic disease state and further comprising:
administering a therapeutic dosage of a therapeutic for the coronavirus disease to the subject, the therapeutic being selected from the group consisting of remdesivir, baricitinib, tocilizumab, a monoclonal antibody treatment, Nirmatrelvir with Ritonavi, Molnupiravir, and/or an immune checkpoint inhibitor.

### Claim 122

A method of evaluating a biological sample obtained from a subject with respect to a symptomatic disease state corresponding to a coronavirus disease (COVID), the method comprising:
identifying a peptide structure profile for the biological sample using peptide structure data, the peptide structure profile comprising quantification data for a set of peptide structures associated with the symptomatic disease state,
wherein the set of peptide structures includes at least two peptide structures from a selected group of peptide structures identified in Table 1-1; and
wherein at least two peptide structures in the selected group of peptide structures includes a glycopeptide structure defined by a peptide sequence and a glycan structure linked to a linking site of the peptide sequence;
computing a disease indicator using the peptide structure profile and a model, wherein the disease indicator indicates whether the biological sample is positive for the symptomatic disease state; and
generating at least one of a diagnosis output or a treatment output based on the disease indicator.

### Claim 123 (depends on 122)

The method of claim 122, further comprising receiving peptide structure data corresponding to the biological sample obtained from the subject.

### Claim 124 (depends on 122)

The method of claim 122, wherein the model is a machine learning model and computing the disease indicator comprises:
computing the disease indicator using the machine learning model, the machine learning model including a set of weight coefficients that corresponds to the set of peptide structures, respectively,
wherein the disease indicator comprises at least one of a probability that the subject is positive for the symptomatic disease state, an odds that the subject is positive for the symptomatic disease state, a logarithm of the odds that the subject is positive for the symptomatic disease state, or a classification of the biological sample as either positive or negative for the symptomatic disease state.

### Claim 125 (depends on 122)

The method of claim 122, wherein the model comprises a supervised machine learning model trained using an output of an unsupervised machine learning model that is trained to cluster a plurality of peptide structure profiles for a plurality of subjects according to a plurality of states, the plurality of states including the symptomatic disease state.

### Claim 126 (depends on 122)

The method of claim 122, wherein the treatment output comprises at least one of an identification of a therapeutic to treat the subject, a design for the therapeutic, or a treatment plan for administering the therapeutic.

### Claim 127 (depends on 122)

The method of claim 122, further comprising:
administering a therapeutic dosage of a therapeutic for the coronavirus disease to the subject based on the at least one of the diagnosis output or the treatment output, the therapeutic being selected from the group consisting of remdesivir, baricitinib, tocilizumab, a monoclonal antibody treatment, an immune checkpoint inhibitor, Nirmatrelvir with Ritonavi, Molnupiravir, and a combination thereof.

### Claim 128 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

A method of designing a treatment for a symptomatic disease state of a coronavirus disease (COVID) in a subject, the method comprising:
designing a therapeutic for treating the subject in response to identifying the subject as being positive for the symptomatic disease state using the method of any one of claims 63-85, 87-92, 93-120, or 122-126.

### Claim 129 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

A method of planning a treatment for a symptomatic disease state of a coronavirus disease (COVID) in a subject, the method comprising:
generating a treatment plan for treating the subject in response to identifying the subject as being positive for the symptomatic disease state using the method of any one of claims 63-85, 87-92, 93-120, or 122-126.

### Claim 130 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

A method of manufacturing a treatment for a symptomatic disease state of a coronavirus disease (COVID) in a subject, the method comprising:
manufacturing a therapeutic for treating the subject in response to identifying the subject as being positive for the symptomatic disease state using the method of any one of claims 63-85, 87-92, 93-120, or 122-126.

### Claim 131 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

A method of treating a symptomatic disease state of a coronavirus disease (COVID) in a subject, the method comprising:
administering to the subject a therapeutic to treat the subject based on identifying the subject as being positive for the symptomatic disease state using the method of any one of claims 63-85, 87-92, 93-120, or 122-126.

### Claim 132 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

A method of treating a symptomatic disease state of a coronavirus disease (COVID) in a subject, the method comprising:
selecting a therapeutic to treat the subject based on determining that the subject is responsive to the therapeutic using the method of any of claims 63-85, 87-92, 93-120, or 122-126; and
administering the selected therapeutic to the subject.

### Claim 133

A method for analyzing a set of peptide structures in a sample from a patient, the method comprising:
(a) preparing a patient sample to form a prepared sample comprising a set of peptide structures;
(b) inputting the prepared sample into a reaction monitoring mass spectrometry system to detect a set of product ions associated with each peptide structure of the set of peptide structures, the set of peptide structures comprising at least one of:
a first peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 891±1.0 and ±1.5;
a second peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1111.7±1.0 and ±1.5;
a third peptide structure associated with the corresponding set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 1062.5±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1196.5±1.0 and ±1.5;
a fourth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 1062.5±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1233±1.0 and ±1.5;
a fifth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1167.3±1.0 and ±1.5;
a sixth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1173.1±1.0 and ±1.5;
a seventh peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1327.6±1.0 and ±1.5;
an eighth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1061.9±1.0 and ±1.5;
a ninth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 874.7±1.0 and ±1.5;
a tenth peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1225.8±1.0 and ±1.5;
an 11th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1183.5±1.0 and ±1.5;
a 12th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1114.2±1.0 and ±1.5;
a 13th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1278.3±1.0 and ±1.5;
a 14th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 1453.6±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1055.8±1.0 and ±1.5;
a 15th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1284.6±1.0 and ±1.5;
a 16th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1285.1±1.0 and ±1.5;
a 17th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 991.2±1.0 and ±1.5;
an 18th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1027.7±1.0 and ±1.5;
a 19th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1155±1.0 and ±1.5;
a 20th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1191.2±1.0 and ±1.5;
a 21st peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 878.8±1.0 and ±1.5;
a 22nd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 976.1±1.0 and ±1.5;
a 23rd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1043.8±1.0 and ±1.5;
a 24th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1199.5±1.0 and ±1.5;
a 25th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1366.3±1.0 and ±1.5;
a 26th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 939.1±1.0 and ±1.5;
a 27th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1295±1.0 and ±1.5;
a 28th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 984.7±1.0 and ±1.5;
a 29th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1367.6±1.0 and ±1.5;
a 30th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1199.2±1.0 and ±1.5;
a 31st peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 736.4±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 618.3±1.0 and ±1.5;
a 32nd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 342.2±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 590.3±1.0 and ±1.5;
a 33rd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 609.3±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 819.1±1.0 and ±1.5;
a 34th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 607.3±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 515.8±1.0 and ±1.5;
a 35th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1116.9±1.0 and ±1.5;
a 36th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1154.7±1.0 and ±1.5;
a 37th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1272.6±1.0 and ±1.5;
a 38th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1285.6±1.0 and ±1.5;
a 39th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1441.6±1.0 and ±1.5;
a 40th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1206.3±1.0 and ±1.5;
a 41st peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1179.1±1.0 and ±1.5;
a 42nd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 529.3±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 660.4±1.0 and ±1.5;
a 43rd peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1310.6±1.0 and ±1.5;
a 44th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 1021.4±1.0 and ±1.5;
a 45th peptide structure associated with the set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 234.1±0.5, ±0.8, and ±1.0 and that is characterized as having a precursor ion having an m/z ratio within a range selected from a group consisting of 764.9±1.0 and ±1.5; and
(c) generating quantification data for the set of product ions using the reaction monitoring mass spectrometry system.

### Claim 134 (depends on 133)

The method of claim 133, further comprising, prior to (a), obtaining the sample from the patient.

### Claim 135 (depends on 133)

The method of claim 133, further comprising:
generating a diagnosis output using the quantification data and a model that has been trained using at least one of supervised or unsupervised machine learning.

### Claim 136 (depends on 133)

The method of claim 133, wherein the reaction monitoring mass spectrometry system uses at least one of multiple reaction monitoring mass spectrometry (MRM-MS), or selected reaction monitoring mass spectrometry (SRM-MS) to detect the set of product ions and generate the quantification data.

### Claim 137 (depends on 13336)

The method of claim 13336, wherein the sample comprises a plasma sample.

### Claim 138 (depends on 133)

The method of claim 133, wherein the sample comprises a serum sample.

### Claim 139 (depends on 133)

The method of claim 133, wherein preparing the sample comprises at least one of:
denaturing one or more proteins in the sample to form one or more denatured proteins;
reducing the one or more denatured proteins in the sample to form one or more reduced proteins;
alkylating the one or more proteins in the sample using an alkylating agent to prevent reformation of disulfide bonds in the one or more reduced proteins to form one or more alkylated proteins; or
digesting the one or more alkylated proteins in the sample using a proteolysis catalyst to form the prepared sample comprising the set of peptide structures.

### Claim 140

A composition comprising at least one of peptide structures PS-1 to PS-45 identified in Table 1-1.

### Claim 141

A composition comprising a peptide structure or a product ion, wherein:
the peptide structure or product ion comprises an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NOS: 84-116, corresponding to peptide structures PS-1 to PS-45 in Table 1-1; and
the product ion is selected as one from a group consisting of product ions identified in Table 4-1 including product ions falling within an identified m/z range.

### Claim 142

A composition comprising a glycopeptide structure selected as one from a group of glycopeptide structures consisting of:
a first glycopeptide structure having a monoisotopic mass of 4447.5 and comprising:
the amino acid sequence of SEQ ID NO: 84; and
glycan structure GL NO. 5401 linked to the 12th residue of SEQ ID NO: 84;
a second glycopeptide structure having a monoisotopic mass of 4440.74 and comprising:
the amino acid sequence of SEQ ID NO. 85; and
glycan structure GL NO. 5401 linked to the 15th residue of SEQ ID NO. 85;
a third glycopeptide structure having a monoisotopic mass of 4779.95 and comprising:
the amino acid sequence of SEQ ID NO. 86; and
glycan structure GL NO. 6503 linked to the 15th residue of SEQ ID NO. 86;
a fourth glycopeptide structure having a monoisotopic mass 4926.00 of and comprising:
the amino acid sequence of SEQ ID NO. 86;
glycan structure GL NO. 6513 linked to the 15th residue of SEQ ID NO. 86;
a fifth glycopeptide structure having a monoisotopic mass of 5829.49 and comprising:
the amino acid sequence of SEQ ID NO. 87; and
glycan structure GL NO. 7602 linked to the 15th residue of SEQ ID NO. 87;
a sixth glycopeptide structure having a monoisotopic mass of 3515.36 and comprising:
the amino acid sequence of SEQ ID NO. 88; and
glycan structure GL NO. 5402 linked to the 4th residue of SEQ ID NO. 88;
a seventh glycopeptide structure having a monoisotopic mass of 3979.65 and comprising:
the amino acid sequence of SEQ ID NO. 89; and
glycan structure GL NO. 5420 linked to the 10th residue of SEQ ID NO. 89;
an eighth glycopeptide structure having a monoisotopic mass of 4242.66 and comprising:
the amino acid sequence of SEQ ID NO. 90; and
glycan structure GL NO. 5412 linked to the 10th residue of SEQ ID NO. 90;
a ninth glycopeptide structure having a monoisotopic mass of 2621.06 and comprising:
the amino acid sequence of SEQ ID NO. 91; and
glycan structure GL NO. 5301 linked to the 1st residue of SEQ ID NO. 91;
a tenth glycopeptide structure having a monoisotopic mass of 4900.17 and comprising:
the amino acid sequence of SEQ ID NO. 92; and
glycan structure GL NO. 6411 linked to the 6th residue of SEQ ID NO. 92;
an 11th glycopeptide structure having a monoisotopic mass of 4729.04 and comprising:
the amino acid sequence of SEQ ID NO. 93; and
glycan structure GL NO. 7602 linked to the 6th residue of SEQ ID NO. 93;
a 12th glycopeptide structure having a monoisotopic mass of 4450.92 and comprising:
the amino acid sequence of SEQ ID NO. 94; and
glycan structure GL NO. 5412 linked to the 4th residue of SEQ ID NO. 94;
a 13th glycopeptide structure having a monoisotopic mass of 5107.14 and comprising:
the amino acid sequence of SEQ ID NO. 94; and
glycan structure GL NO. 6513 linked to the 4th residue of SEQ ID NO. 94;
a 14th glycopeptide structure having a monoisotopic mass of 3163.24 and comprising:
the amino acid sequence of SEQ ID NO. 95; and
glycan structure GL NO. 5401 linked to the 3rd residue of SEQ ID NO. 95;
a 15th glycopeptide structure having a monoisotopic mass of 5133.19 and comprising:
the amino acid sequence of SEQ ID NO. 96; and
glycan structure GL NO. 5402 linked to the 19th residue of SEQ ID NO. 96;
a 16th glycopeptide structure having a monoisotopic mass of 5133.19 and comprising:
the amino acid sequence of SEQ ID NO. 96; and
glycan structure GL NO. 5421 linked to the 19th residue of SEQ ID NO. 96;
a 17th glycopeptide structure having a monoisotopic mass of 3959.66 and comprising:
the amino acid sequence of SEQ ID NO. 97; and
glycan structure GL NO. 5402 linked to the 4th residue of SEQ ID NO. 97;
an 18th glycopeptide structure having a monoisotopic mass of 4105.72 and comprising:
the amino acid sequence of SEQ ID NO. 97; and
glycan structure GL NO. 5412 linked to the 4th residue of SEQ ID NO. 97;
a 19th glycopeptide structure having a monoisotopic mass of 4615.89 and comprising:
the amino acid sequence of SEQ ID NO. 97; and
glycan structure GL NO. 6503 linked to the 4th residue of SEQ ID NO. 97;
a 20th glycopeptide structure having a monoisotopic mass of 4758.93 and comprising:
the amino acid sequence of SEQ ID NO. 98; and
glycan structure GL NO. 6513 linked to the 4th residue of SEQ ID NO. 98;
a 21st glycopeptide structure having a monoisotopic mass of 2633.04 and comprising:
the amino acid sequence of SEQ ID NO. 99; and
glycan structure GL NO. 3410 linked to the 5th residue of SEQ ID NO. 99;
a 22nd glycopeptide structure having a monoisotopic mass of 2925.15 and comprising:
the amino acid sequence of SEQ ID NO. 99; and
glycan structure GL NO. 5410 linked to the 5th residue of SEQ ID NO. 99;
a 23rd glycopeptide structure having a monoisotopic mass of 3128.23 and comprising:
the amino acid sequence of SEQ ID NO. 99; and
glycan structure GL NO. 5510 linked to the 5th residue of SEQ ID NO. 99;
a 24th glycopeptide structure having a monoisotopic mass of 4677.79 and comprising:
the amino acid sequence of SEQ ID NO. 100; and
glycan structure GL NO. 6503 linked to the 9th residue of SEQ ID NO. 100;
a 25th glycopeptide structure having a monoisotopic mass of 6822.70 and comprising:
the amino acid sequence of SEQ ID NO. 101; and
glycan structure GL NO. 5402 linked to the 9th residue of SEQ ID NO. 101;
a 26th glycopeptide structure having a monoisotopic mass of 2813.31 and comprising:
the amino acid sequence of SEQ ID NO. 102; and
glycan structure GL NO. 1101 linked to the 12th residue of SEQ ID NO. 102;
a 27th glycopeptide structure having a monoisotopic mass of 5174.11 and comprising:
the amino acid sequence of SEQ ID NO. 103; and
glycan structure GL NO. 6523 linked to the 9th residue of SEQ ID NO. 103;
a 28th glycopeptide structure having a monoisotopic mass of 3933.66 and comprising:
the amino acid sequence of SEQ ID NO. 104; and
glycan structure GL NO. 5401 linked to the 15th residue of SEQ ID NO. 104;
a 29th glycopeptide structure having a monoisotopic mass of 5463.24 and comprising:
the amino acid sequence of SEQ ID NO. 105; and
glycan structure GL NO. 5401 linked to the 16th residue of SEQ ID NO. 105;
a 30th glycopeptide structure having a monoisotopic mass of 4791.91 and comprising:
the amino acid sequence of SEQ ID NO. 106; and
glycan structure GL NO. 7420 linked to the 4th residue of SEQ ID NO. 106;
a 31st glycopeptide structure having a monoisotopic mass of 5578.17 and comprising:
the amino acid sequence of SEQ ID NO. 111; and
glycan structure GL NO. 7614 linked to the 7th residue of SEQ ID NO. 111;
a 32th glycopeptide structure having a monoisotopic mass of 4612.87 and comprising:
the amino acid sequence of SEQ ID NO. 98; and
glycan structure GL NO. 6503 linked to the 4th residue of SEQ ID NO. 98;
a 33rd glycopeptide structure having a monoisotopic mass of 5084.28 and comprising:
the amino acid sequence of SEQ ID NO. 112; and
glycan structure GL NO. 5401 linked to the 17th residue of SEQ ID NO. 112;
a 34th glycopeptide structure having a monoisotopic mass of 3853.74 and comprising:
the amino acid sequence of SEQ ID NO. 93; and
glycan structure GL NO. 5411 linked to the 6th residue of SEQ ID NO. 93;
a 35th glycopeptide structure having a monoisotopic mass of 4321.78 and comprising:
the amino acid sequence of SEQ ID NO. 98; and
glycan structure GL NO. 6502 linked to the 4th residue of SEQ ID NO. 98;
a 36th glycopeptide structure having a monoisotopic mass of 8432.83 and comprising:
the amino acid sequence of SEQ ID NO. 113; and
glycan structure GL NO. 5402 linked to the 46th residue of SEQ ID NO. 113;
a 37th glycopeptide structure having a monoisotopic mass of 5890.66 and comprising:
the amino acid sequence of SEQ ID NO. 97; and
glycan structure GL NO. 5412 linked to the 4th residue of SEQ ID NO. 97;
a 38th glycopeptide structure having a monoisotopic mass of 3927.64 and comprising:
the amino acid sequence of SEQ ID NO. 115; and
glycan structure GL NO. 5401 linked to the 5th residue of SEQ ID NO. 115;
a 39th glycopeptide structure having a monoisotopic mass of 4079.71 and comprising:
the amino acid sequence of SEQ ID NO. 104; and
glycan structure GL NO. 5411 linked to the 15th residue of SEQ ID NO. 104; and
wherein:
the glycan structure GL NO. 1101 comprises:
the glycan structure GL NO. 3410 comprises:
the glycan structure GL NO. 5401 comprises:
the glycan structure (GL NO. 5402) comprises:
the glycan structure (GL NO. 5410) comprises:
the glycan structure (GL NO. 5411) comprises:
the glycan structure (GL NO. 5412) comprises:
the glycan structure (GL NO. 5420) comprises:
the glycan structure (GL NO. 5510) comprises:
the glycan structure (GL NO. 6411) comprises:
the glycan structure (GL NO. 6502) comprises:
the glycan structure (GL NO. 6503) comprises:
the glycan structure (GL NO. 6523) comprises:
the glycan structure (GL NO. 7420) comprises:
the glycan structure (GL NO. 7602) comprises:

### Claim 143 (depends on 142)

The composition of claim 142, wherein:
the first glycopeptide structure has a precursor ion having a charge of 5;
the second glycopeptide structure has a precursor ion having a charge of 4;
the third glycopeptide structure has a precursor ion having a charge of 4;
the fourth glycopeptide structure has a precursor ion having a charge of 4;
the fifth glycopeptide structure has a precursor ion having a charge of 5;
the sixth glycopeptide structure has a precursor ion having a charge of 3;
the seventh glycopeptide structure has a precursor ion having a charge of 3;
the eighth glycopeptide structure has a precursor ion having a charge of 4;
the ninth glycopeptide structure has a precursor ion having a charge of 3;
the tenth glycopeptide structure has a precursor ion having a charge of 4;
the 11th glycopeptide structure has a precursor ion having a charge of 4;
the 12th glycopeptide structure has a precursor ion having a charge of 4;
the 13th glycopeptide structure has a precursor ion having a charge of 4;
the 14th glycopeptide structure has a precursor ion having a charge of 3;
the 15th glycopeptide structure has a precursor ion having a charge of 4;
the 16th glycopeptide structure has a precursor ion having a charge of 4;
the 17th glycopeptide structure has a precursor ion having a charge of 4;
the 18th glycopeptide structure has a precursor ion having a charge of 4;
the 19th glycopeptide structure has a precursor ion having a charge of 4;
the 20th glycopeptide structure has a precursor ion having a charge of 4;
the 21st glycopeptide structure has a precursor ion having a charge of 3;
the 22nd glycopeptide structure has a precursor ion having a charge of 3;
the 23rd glycopeptide structure has a precursor ion having a charge of 3;
the 24th glycopeptide structure has a precursor ion having a charge of 4;
the 25th glycopeptide structure has a precursor ion having a charge of 5;
the 26th glycopeptide structure has a precursor ion having a charge of 3;
the 27th glycopeptide structure has a precursor ion having a charge of 4;
the 28th glycopeptide structure has a precursor ion having a charge of 4;
the 29th glycopeptide structure has a precursor ion having a charge of 4;
the 30th glycopeptide structure has a precursor ion having a charge of 4;
the 31st glycopeptide structure has a precursor ion having a charge of 5;
the 32th glycopeptide structure has a precursor ion having a charge of 4;
the 33rd glycopeptide structure has a precursor ion having a charge of 4;
the 34th glycopeptide structure has a precursor ion having a charge of 3;
the 35th glycopeptide structure has a precursor ion having a charge of 3;
the 36th glycopeptide structure has a precursor ion having a charge of 7;
the 37th glycopeptide structure has a precursor ion having a charge of 5;
the 38th glycopeptide structure has a precursor ion having a charge of 3; and
the 39th glycopeptide structure has a precursor ion having a charge of 4.

### Claim 144 (depends on 142)

The composition of claim 142, wherein:
the first glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the second glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0;
the third glycopeptide structure associated with the corresponding set of product ions that includes a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 1062.5±0.5, ±0.8, and ±1.0;
the fourth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 1062.5±0.5, ±0.8, and ±1.0;
the fifth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the sixth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the seventh glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the eighth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the ninth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the tenth glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 11th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 12th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0;
the 13th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0;
the 14th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 1453.6±0.5, ±0.8, and ±1.0;
the 15th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 16th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 17th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 18th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 19th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0;
the 20th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 21st glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 204.1±0.5, ±0.8, and ±1.0;
the 22nd glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 23rd glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 24th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 25th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 26th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0;
the 27th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0;
the 28th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 29th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 30th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 31st glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 32nd glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 274.1±0.5, ±0.8, and ±1.0;
the 33rd glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 34th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 35th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 36th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 37th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0;
the 39th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0; and
the 39th glycopeptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 366.1±0.5, ±0.8, and ±1.0.

### Claim 145 (depends on 142)

The composition of claim 142, wherein:
the first glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 891±1.0 and ±1.5;
the second glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1111.7±1.0 and ±1.5;
the third glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1196.5±1.0 and ±1.5;
the fourth glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1233±1.0 and ±1.5;
the fifth glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1167.3±1.0 and ±1.5;
the sixth glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1173.1±1.0 and ±1.5;
the seventh glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1327.6±1.0 and ±1.5;
the eighth glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1061.9±1.0 and ±1.5;
the ninth glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 874.7±1.0 and ±1.5;
the tenth glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1225.8±1.0 and ±1.5;
the 11th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1183.5±1.0 and ±1.5;
the 12th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1114.2±1.0 and ±1.5;
the 13th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1278.3±1.0 and ±1.5;
the 14th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1055.8±1.0 and ±1.5;
the 15th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1284.6±1.0 and ±1.5;
the 16th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1285.1±1.0 and ±1.5;
the 17th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 991.2±1.0 and ±1.5;
the 18th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1027.7±1.0 and ±1.5;
the 19th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1155±1.0 and ±1.5;
the 20th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1191.2±1.0 and ±1.5;
the 21st glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 878.8±1.0 and ±1.5;
the 22nd glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 976.1±1.0 and ±1.5;
the 23rd glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1043.8±1.0 and ±1.5;
the 24th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1199.5±1.0 and ±1.5;
the 25th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1366.3±1.0 and ±1.5;
the 26th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 939.1±1.0 and ±1.5;
the 27th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1295±1.0 and ±1.5;
the 28th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 984.7±1.0 and ±1.5;
the 29th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1367.6±1.0 and ±1.5;
the 30th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1199.2±1.0 and ±1.5;
the 31st glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1116.9±1.0 and ±1.5;
the 32nd glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1154.7±1.0 and ±1.5;
the 33rd glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1272.6±1.0 and ±1.5;
the 34th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1285.6±1.0 and ±1.5;
the 35th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1441.6±1.0 and ±1.5;
the 36th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1206.3±1.0 and ±1.5;
the 37th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1179.1±1.0 and ±1.5;
the 39th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1310.6±1.0 and ±1.5; and
the 40th glycopeptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 1021.4±1.0 and ±1.5.

### Claim 146

A composition comprising a peptide structure selected as one from a group of aglycosylated peptide structures consisting of:
a first peptide structure having a monoisotopic mass of 1234.68 and comprising the amino acid sequence of SEQ ID NO: 107;
a second peptide structure having a monoisotopic mass of 1178.67 comprising the amino acid sequence of SEQ ID NO: 108;
a third peptide structure having a monoisotopic mass of 2454.14 comprising the amino acid sequence of SEQ ID NO: 109;
a fourth peptide structure having a monoisotopic mass of 1029.53 comprising the amino acid sequence of SEQ ID NO: 110;
a fifth peptide structure having a monoisotopic mass of 1318.73 comprising the amino acid sequence of SEQ ID NO: 114; and
a sixth peptide structure having a monoisotopic mass of 1527.74 comprising the amino acid sequence of SEQ ID NO: 116.

### Claim 147 (depends on 146)

The composition of claim 146, wherein:
the first peptide structure has a precursor ion having a charge of 2;
the second peptide structure has a precursor ion having a charge of 2;
the third peptide structure has a precursor ion having a charge of 3;
the fourth peptide structure has a precursor ion having a charge of 2;
the fifth peptide structure has a precursor ion having a charge of 2; and
the sixth peptide structure has a precursor ion having a charge of 2.

### Claim 148 (depends on 146)

The composition of claim 146, wherein:
the first peptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 736.4±0.5, ±0.8, and ±1.0;
the second peptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 342.2±0.5, ±0.8, and ±1.0;
the third peptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 609.3±0.5, ±0.8, and ±1.0;
the fourth peptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 607.3±0.5, ±0.8, and ±1.0;
the fifth peptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 529.3±0.5, ±0.8, and ±1.0; and
the sixth peptide structure has a product ion having a mass-to-charge (m/z) ratio that is within a range selected from a group consisting of 234.1±0.5, ±0.8, and ±1.0.

### Claim 149 (depends on 146)

The composition of claim 146, wherein:
the first peptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 618.3±1.0 and ±1.5;
the second peptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 590.3±1.0 and ±1.5;
the third peptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 819.1±1.0 and ±1.5;
the fourth peptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 515.8±1.0 and ±1.5;
the fifth peptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 660.4±1.0 and ±1.5; and
the sixth peptide structure has a precursor ion having an m/z ratio within a range selected from a group consisting of 764.9±1.0 and ±1.5.

### Claim 150 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139)

A kit comprising at least one agent for quantifying at least one peptide structure identified in Table 1-1 to carry out the method of any one of claims 63-139.

### Claim 151 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139)

A kit comprising at least one of a glycopeptide standard, a buffer, or a set of peptide sequences to carry out the method of any one of claims 63-139, a peptide sequence of the set of peptide sequences identified by a corresponding one of SEQ ID NOS: 84-116, defined in Table 5-1.

### Claim 152 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

A system comprising:
one or more data processors; and
a non-transitory computer readable storage medium containing instructions which, when executed on the one or more data processors, cause the one or more data processors to perform part or all of any one of claims 63-85, 87-92, 93-120, or 122-126.

### Claim 153

A method of diagnosing a coronavirus disease (COVID) in a subject, comprising the step of identifying one or more peptide structures identified in Table 2-1 from a sample from the subject.

### Claim 154 (depends on 153)

The method of claim 153, wherein the sample comprises blood, plasma, serum, urine, saliva, mucosal excretions, sputum, stool, nasal mucus, phlegm, and/or tears.

### Claim 155 (depends on 153, 154)

The method of claim 153 or 154, wherein the step of identifying occurs once.

### Claim 156 (depends on 153, 154)

The method of claim 153 or 154, wherein the step of identifying occurs multiple times.

### Claim 157 (depends on 156)

The method of claim 156, wherein one or more symptoms becomes undetectable between multiple identifying steps.

### Claim 158 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 122, 123, 124, 125, 126)

A method of identifying or managing an at-risk subject for a coronavirus disease (COVID), the method comprising measuring whether a biological sample obtained from the subject evidences COVID using part or all of the method of any one of claims 63-85, 87-92, 93-120, 122-126, or 153-157, and
subjecting the subject to one or more medical tests or procedures, and/or
subjecting the subject to one or more preventatives or therapies in response to the identification of the symptomatic disease state.

### Claim 159 (depends on 158)

The method of claim 158, wherein the subject has one or more COVID symptoms at the time of measuring and/or at the time of obtaining the sample.

### Claim 160 (depends on 158)

The method of claim 158, wherein the subject is asymptomatic at the time of measuring and/or at the time of obtaining the sample.

### Claim 161

A method of identifying a subject suitable for, or in need of, COVID prevention or treatment, the method comprising the step of measuring from a biological sample taken from the subject for the presence of one or a combination of peptide structures identified in Table 2-1, wherein their detection indicates that the subject should have COVID prevention or treatment.

### Claim 162 (depends on 161)

The method of claim 161, wherein the subject has one or more COVID symptoms at the time of measuring and/or at the time of obtaining the sample.

### Claim 163 (depends on 161)

The method of claim 161, wherein the subject is asymptomatic at the time of measuring and/or at the time of obtaining the sample.

### Claim 164

A method of predicting whether a subject will be symptomatic upon coronavirus infection, comprising the step of measuring from a biological sample taken from the subject for the presence of one or a combination of peptide structures identified in Table 2-1.

### Claim 165 (depends on 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 122, 123, 124, 125, 126)

A computer-program product tangibly embodied in a non-transitory machine-readable storage medium, including instructions configured to cause one or more data processors to perform part or all of any one of claims 63-85, 87-92, 93-120, 122-126, or 154-164.
